Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | POLB | P06746 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24045260 | 0.94 | MAPT (0.75) | MAPTPOLBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL26687676 | 0.94 | MAPT (0.75) | MAPTPOLBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL24045322 | 0.94 | MAPT (0.75) | MAPTPOLBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL24045329 | 0.92 | TP53 (0.81) | MAPTPOLBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL24045100 | 0.91 | MAPK1 (0.75) | MAPTPOLBTP53 | |
| SCHEMBL26687688 | 0.90 | MAPT (0.70) | MAPTPOLBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL24045351 | 0.90 | MAPT (0.70) | MAPTPOLBSMN1; SMN2TP53 | |
| SCHEMBL24045327 | 0.89 | MAPT (0.79) | MAPTPOLBALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL26687689 | 0.88 | MAPT (0.83) | MAPTPOLBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL24045321 | 0.84 | MAPT (0.89) | MAPTPOLBLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-26 | — | — | US | disclosed |
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | MAPT 2923/4885POLB 1871/4885LMNA 3821/4885 |
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | MAPT 3087/4885POLB 2167/4885LMNA 4229/4885 |
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | SLC26A3, SLC10A2, SLC10A6 | MAPT 3087/4885POLB 2167/4885LMNA 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.